PharMerica Corporation is an institutional pharmacy services company. The Company services healthcare facilities, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the national oncology pharmacy in the United States. Its segments include institutional pharmacy, which provides pharmacy products and services to residents and patients in skilled nursing facilities, nursing centers, assisted living facilities, hospitals and other long-term alternative care settings; specialty infusion services, which provides specialty infusion services focused on providing pharmaceutical products and clinical services to patients in client facilities, hospice and outside of hospital or nursing home settings, and specialty oncology pharmacy, which provides dispensing of oncology drugs, care management and other related services to patients, oncology practices and hospitals.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Stores
- Sub-Industry: Health Care Distributors
- Symbol: NYSE:PMC
- CUSIP: 71714F10
- Web: www.pharmerica.com
Capitalization:- Market Cap: $782.01 million
- Outstanding Shares: 31,094,000
Average Prices:- 50 Day Moving Avg: $23.97
- 200 Day Moving Avg: $24.42
- 52 Week Range: $19.20 - $28.72
P/E:- Trailing P/E Ratio: 37.54
- Foreward P/E Ratio: 11.59
- P/E Growth: 1.37
Sales & Book Value:- Annual Revenue: $2.13 billion
- Price / Sales: 0.37
- Book Value: $17.70 per share
- Price / Book: 1.42
Profitability:- EBIDTA: $130.2 million
- Net Margins: 1.64%
- Return on Equity: 10.40%
- Return on Assets: 4.68%
Debt:- Debt-to-Equity Ratio: 0.71%
- Current Ratio: 3.10%
- Quick Ratio: 2.25%
Misc:- Average Volume: 198,823 shs.
- Beta: 1.1
- Short Ratio: 4.22
Frequently Asked Questions for PharMerica (NYSE:PMC)
What is PharMerica's stock symbol?
PharMerica trades on the New York Stock Exchange (NYSE) under the ticker symbol "PMC."
How were PharMerica's earnings last quarter?
PharMerica Co. (NYSE:PMC) announced its quarterly earnings data on Wednesday, May, 10th. The company reported $0.42 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.02. The business earned $566.80 million during the quarter, compared to analysts' expectations of $536.85 million. PharMerica had a return on equity of 10.40% and a net margin of 1.64%. The firm's quarterly revenue was up 8.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.45 earnings per share. View PharMerica's Earnings History.
What guidance has PharMerica issued on next quarter's earnings?
PharMerica updated its FY17 earnings guidance on Wednesday, May, 10th. The company provided EPS guidance of $1.75-1.95 for the period, compared to the Thomson Reuters consensus estimate of $1.89. The company issued revenue guidance of $2.3-2.4 billion, compared to the consensus revenue estimate of $2.35 billion.
Where is PharMerica's stock going? Where will PharMerica's stock price be in 2017?
1 brokers have issued 12 month price targets for PharMerica's shares. Their predictions range from $32.00 to $32.00. On average, they expect PharMerica's stock price to reach $32.00 in the next twelve months. View Analyst Ratings for PharMerica.
Who are some of PharMerica's key competitors?
Some companies that are related to PharMerica include DBV Technologies SA - (DBVT), Omnicell (OMCL), HMS Holdings Corp (HMSY), Lexicon Pharmaceuticals (LXRX), NxStage Medical (NXTM), Accelerate Diagnostics (AXDX), Beigene Ltd (BGNE), MiMedx Group (MDXG), Array Biopharma (ARRY), CONMED (CNMD), Foundation Medicine (FMI), Myriad Genetics (MYGN), Phibro Animal Health Corp (PAHC), Glaukos Corp (GKOS), Corcept Therapeutics Incorporated (CORT), Innoviva (INVA), Repligen (RGEN) and Tivity Health (TVTY).
Who owns PharMerica stock?
PharMerica's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.91%), Dimensional Fund Advisors LP (8.46%), FMR LLC (6.46%), Vanguard Group Inc. (5.08%), Boston Partners (4.04%) and Victory Capital Management Inc. (3.00%). Company insiders that own PharMerica stock include Gregory S Weishar, Mark Lindemoen and Robert A Mckay. View Institutional Ownership Trends for PharMerica.
Who sold PharMerica stock? Who is selling PharMerica stock?
PharMerica's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., FMR LLC, Teachers Advisors LLC, Ameriprise Financial Inc., Bank of New York Mellon Corp, Systematic Financial Management LP, Victory Capital Management Inc. and Boston Partners. View Insider Buying and Selling for PharMerica.
Who bought PharMerica stock? Who is buying PharMerica stock?
PharMerica's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Sessa Capital IM L.P., Citadel Advisors LLC, Bank of America Corp DE, LSV Asset Management, First Trust Advisors LP, State Street Corp and Morgan Stanley. View Insider Buying and Selling for PharMerica.
How do I buy PharMerica stock?
Shares of PharMerica can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of PharMerica stock cost?
One share of PharMerica stock can currently be purchased for approximately $25.15.
Earnings History for PharMerica (NYSE:PMC)Earnings History by Quarter for PharMerica (NYSE:PMC)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/10/2017 | Q1 2017 | $0.40 | $0.42 | $536.85 million | $566.80 million | View | N/A |  |
| 2/24/2017 | Q416 | $0.51 | $0.58 | $525.22 million | $534.40 million | View | Listen | |
| 11/9/2016 | Q316 | $0.51 | $0.44 | $530.01 million | $512.60 million | View | Listen | |
| 8/9/2016 | Q216 | $0.47 | $0.47 | $508.31 million | $519.60 million | View | Listen | |
| 5/6/2016 | Q116 | $0.43 | $0.45 | $509.45 million | $524.50 million | View | Listen | |
| 2/26/2016 | Q415 | $0.41 | $0.45 | $506.40 million | $520.60 million | View | Listen | |
| 11/6/2015 | Q315 | $0.36 | $0.39 | $480.35 million | $498.80 million | View | Listen | |
| 8/7/2015 | Q215 | $0.33 | $0.37 | $491.66 million | $497.50 million | View | Listen | |
| 5/7/2015 | Q115 | $0.43 | $0.48 | $500.95 million | $511.60 million | View | Listen | |
| 3/2/2015 | Q414 | $0.43 | $0.45 | $491.99 million | $523.50 million | View | Listen | |
| 11/6/2014 | Q314 | $0.40 | $0.45 | $439.63 million | $470.20 million | View | Listen | |
| 8/5/2014 | Q214 | $0.36 | $0.40 | $432.70 million | $448.60 million | View | Listen | |
| 5/1/2014 | Q114 | $0.33 | $0.37 | $417.76 million | $452.20 million | View | Listen | |
| 2/28/2014 | Q413 | $0.38 | $0.44 | $421.16 million | $433.20 million | View | Listen | |
| 11/5/2013 | Q313 | $0.32 | $0.49 | $398.02 million | $442.00 million | View | Listen | |
| 8/2/2013 | Q2 2013 | $0.34 | $0.44 | $414.15 million | $458.50 million | View | Listen | |
| 5/1/2013 | Q1 2013 | $0.34 | $0.46 | $435.10 million | $439.80 million | View | Listen | |
| 2/7/2013 | Q4 2012 | $0.29 | $0.12 | $432.43 million | $433.20 million | View | Listen | |
| 11/1/2012 | Q312 | $0.30 | $0.33 | $446.36 million | $442.00 million | View | N/A | |
| 8/2/2012 | | $0.30 | $0.32 | | | View | N/A | |
| 5/2/2012 | | $0.27 | $0.30 | | | View | N/A | |
| 2/9/2012 | | $0.21 | $0.27 | | | View | N/A | |
| 11/3/2011 | | $0.20 | $0.31 | | | View | N/A | |
| 8/4/2011 | | $0.20 | $0.32 | | | View | N/A | |
| 5/5/2011 | | $0.20 | $0.21 | | | View | N/A | |
| 2/24/2011 | | $0.17 | $0.16 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for PharMerica (NYSE:PMC)2017 EPS Consensus Estimate: $1.88
2018 EPS Consensus Estimate: $2.12
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.40 | $0.40 | $0.40 |
| Q2 2017 | 2 | $0.46 | $0.47 | $0.47 |
| Q3 2017 | 2 | $0.48 | $0.49 | $0.49 |
| Q4 2017 | 2 | $0.53 | $0.53 | $0.53 |
| Q1 2018 | 1 | $0.48 | $0.48 | $0.48 |
| Q2 2018 | 1 | $0.52 | $0.52 | $0.52 |
| Q3 2018 | 1 | $0.55 | $0.55 | $0.55 |
| Q4 2018 | 1 | $0.57 | $0.57 | $0.57 |
(Data provided by Zacks Investment Research)
Dividend History for PharMerica (NYSE:PMC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for PharMerica (NYSE:PMC)Insider Ownership Percentage: 5.04%
Institutional Ownership Percentage: 97.15%
Insider Trades by Quarter for PharMerica (NYSE:PMC)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 12/2/2015 | Robert A Mckay | SVP | Sell | 2,993 | $34.42 | $103,019.06 | |
| 11/11/2015 | Mark Lindemoen | SVP | Sell | 3,790 | $34.71 | $131,550.90 | |
| 6/16/2015 | Robert A Mckay | SVP | Sell | 7,000 | $32.75 | $229,250.00 | |
| 6/3/2015 | Gregory S Weishar | CEO | Sell | 104,150 | $32.63 | $3,398,414.50 | |
| 6/1/2015 | Mark Lindemoen | SVP | Sell | 4,500 | $33.27 | $149,715.00 | |
| 3/12/2015 | Berard Tomassetti | CAO | Sell | 3,344 | $26.44 | $88,415.36 | |
| 3/12/2015 | Thomas A Caneris | SVP | Sell | 7,495 | $26.52 | $198,767.40 | |
| 3/6/2015 | Robert A Mckay | SVP | Sell | 20,000 | $26.74 | $534,800.00 | |
| 8/8/2014 | Robert A Oakley | Director | Sell | 8,399 | $26.55 | $222,993.45 | |
| 5/13/2014 | Thomas Caneris | SVP | Sell | 12,192 | $28.60 | $348,691.20 | |
| 3/14/2014 | Gregory Weishar | CEO | Sell | 60,000 | $26.27 | $1,576,200.00 | |
| 3/13/2014 | Robert Mckay | SVP | Sell | 18,646 | $26.08 | $486,287.68 | |
| 3/12/2014 | Berard Tomassetti | CAO | Sell | 3,812 | $25.22 | $96,138.64 | |
| 3/6/2014 | Thomas Caneris | SVP | Sell | 14,357 | $25.60 | $367,539.20 | |
| 11/22/2013 | Thomas Gerrity | Director | Sell | 3,271 | $20.56 | $67,251.76 | |
| 11/15/2013 | Berard Tomassetti | CAO | Sell | 4,097 | $20.55 | $84,193.35 | |
| 5/30/2013 | Berard Tomassetti | CAO | Sell | 9,724 | $15.68 | $152,472.32 | |
(Data available from 1/1/2013 forward)
Headline Trends for PharMerica (NYSE:PMC)
Latest Headlines for PharMerica (NYSE:PMC)
| Source: |
|
| Date | Headline |
|---|
 | KeyCorp Analysts Increase Earnings Estimates for PharMerica Co. (PMC)
www.americanbankingnews.com - May 17 at 8:44 AM |
 | Edited Transcript of PMC earnings conference call or presentation 10-May-17 2:00pm GMT
finance.yahoo.com - May 16 at 9:48 AM |
| PharMerica Co. (PMC) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - May 16 at 8:10 AM |
| PharMerica Co. Expected to Earn Q2 2017 Earnings of $0.46 Per Share (PMC)
www.americanbankingnews.com - May 16 at 7:52 AM |
| Q2 2017 Earnings Estimate for PharMerica Co. Issued By Barrington Research (PMC)
www.americanbankingnews.com - May 15 at 7:30 AM |
| $573.5 Million in Sales Expected for PharMerica Co. (PMC) This Quarter
www.americanbankingnews.com - May 13 at 7:38 AM |
| Research Analysts Issue Forecasts for PharMerica Co.'s Q4 2017 Earnings (PMC)
www.americanbankingnews.com - May 12 at 3:24 PM |
| Brokerages Anticipate PharMerica Co. (PMC) Will Post Earnings of $0.46 Per Share
www.americanbankingnews.com - May 11 at 8:20 PM |
| PharMerica beats 1Q estimates, reveals acquisition
finance.yahoo.com - May 10 at 7:29 PM |
| PharMerica Co. (PMC) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 10 at 4:16 PM |
| PharMerica Reports First Quarter 2017 Results
finance.yahoo.com - May 10 at 11:36 AM |
| PharMerica beats 1Q profit forecasts
finance.yahoo.com - May 10 at 11:36 AM |
| PharMerica Co. (PMC) Releases FY17 Earnings Guidance
www.americanbankingnews.com - May 10 at 9:00 AM |
| PharMerica (PMC) Earns Daily News Impact Score of 0.16
www.americanbankingnews.com - May 4 at 12:06 PM |
| Pharmerica reveals how much executives made in 2016
finance.yahoo.com - May 2 at 5:04 PM |
| Positive News Coverage Likely to Affect PharMerica (PMC) Stock Price
www.americanbankingnews.com - April 29 at 10:22 PM |
| PharMerica Corp. – Value Analysis (NYSE:PMC) : April 27, 2017
finance.yahoo.com - April 27 at 7:43 PM |
| PharMerica Corp. breached its 50 day moving average in a Bullish Manner : PMC-US : April 26, 2017
finance.yahoo.com - April 26 at 6:01 PM |
| $536.5 Million in Sales Expected for PharMerica Co. (PMC) This Quarter
www.americanbankingnews.com - April 23 at 10:19 AM |
| PharMerica Corporation Announces First Quarter 2017 Earnings Call and Webcast
finance.yahoo.com - April 19 at 7:16 PM |
| PharMerica (PMC) Earns Daily Media Impact Rating of 0.69
www.americanbankingnews.com - April 16 at 7:52 AM |
| PharMerica Announces Date of 2017 Annual Meeting of Shareholders
finance.yahoo.com - April 7 at 7:37 PM |
| PHARMERICA CORP Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statem
biz.yahoo.com - March 30 at 7:31 PM |
 | PharMerica Acquires CareMed Specialty Pharmacy
us.rd.yahoo.com - March 16 at 7:59 PM |
| PharMerica Co. (PMC) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - March 12 at 6:21 PM |
| PharMerica (PMC): Moving Average Crossover Alert
finance.yahoo.com - March 8 at 4:02 PM |
| PHARMERICA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
biz.yahoo.com - February 27 at 9:48 AM |
| PharMerica Corp Earnings Call scheduled for 10:00 am ET today
us.rd.yahoo.com - February 25 at 1:28 AM |
| Edited Transcript of PMC earnings conference call or presentation 24-Feb-17 3:00pm GMT
us.rd.yahoo.com - February 25 at 1:28 AM |
| PharMerica beats 4Q profit forecasts
finance.yahoo.com - February 24 at 8:27 PM |
 | PharMerica's (PMC) CEO Greg Weishar on Q4 2016 Results - Earnings Call Transcript
seekingalpha.com - February 24 at 8:27 PM |
 | Pharmerica increases goal for merger revenue in Q4 earnings call
www.bizjournals.com - February 24 at 8:27 PM |
| Q4 2016 PharMerica Corp Earnings Release - Before Market Open
biz.yahoo.com - February 24 at 8:28 AM |
| PharMerica Reports Fourth Quarter and Full Year 2016 Results
finance.yahoo.com - February 24 at 8:28 AM |
| PharMerica Corporation Announces Fourth Quarter and Year End 2016 Earnings Call and Webcast
finance.yahoo.com - February 3 at 8:08 PM |
| PharMerica hires a new top executive
www.bizjournals.com - February 1 at 9:56 PM |
 | Pharmerica (PMC) Names Robert Dries as CFO
www.streetinsider.com - February 1 at 9:56 PM |
| PharMerica Appoints Robert E. Dries as Executive Vice President and Chief Financial Officer
us.rd.yahoo.com - February 1 at 9:56 PM |
| 9:01 am PharMerica appoints Robert E. Dries as Chief Financial Officer effective January 31
us.rd.yahoo.com - February 1 at 9:56 PM |
| PharMerica Announces Expansion of Existing Credit Facility, Increasing Borrowing Capacity by $150 Million
finance.yahoo.com - December 15 at 8:31 PM |
| 4:20 pm PharMerica amends its existing credit agreement with Bank of America to increase the Co's borrowing capacity by approx. $150 million;
finance.yahoo.com - December 15 at 8:31 PM |
| PHARMERICA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial S
biz.yahoo.com - December 15 at 8:31 PM |
| PHARMERICA CORP Financials
finance.yahoo.com - November 17 at 6:35 PM |
PharMerica (PMC) Chart for Friday, May, 26, 2017
